These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33600060)

  • 1. Randomized trial of different initial intravenous immunoglobulin regimens in Kawasaki disease.
    He L; Liu F; Yan W; Huang M; Huang M; Xie L; Guo Y; Xu X; Chu C; Wu L; Liang X; Sun S; Wang F; Zhao L; Zhao Q; Ma X; Xie L; Huang G
    Pediatr Int; 2021 Jul; 63(7):757-763. PubMed ID: 33600060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
    Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
    Burns JC; Roberts SC; Tremoulet AH; He F; Printz BF; Ashouri N; Jain SS; Michalik DE; Sharma K; Truong DT; Wood JB; Kim KK; Jain S;
    Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
    Eleftheriou D; Moraes YC; Purvis C; Pursell M; Morillas MM; Kahn R; Mossberg M; Kucera F; Tulloh R; Standing JF; Swallow V; McCormack R; Herberg J; Levin M; Wan M; Klein N; Connon R; Walker AS; Brogan P
    Trials; 2023 Jan; 24(1):60. PubMed ID: 36703139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
    Lei WT; Chang LS; Zeng BY; Tu YK; Uehara R; Matsuoka YJ; Su KP; Lee PC; Cavalcante JL; Stubbs B; Lin PY; Wu YC; Hsu CW; Chen TY; Chen YW; Yeh PY; Sun CK; Tseng PT; Kao YH
    EBioMedicine; 2022 Apr; 78():103946. PubMed ID: 35306339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of immunoglobulin plus prednisolone in reducing coronary artery lesions in patients with Kawasaki disease: study protocol for a phase III multicenter, open-label, blinded-endpoints randomized controlled trial.
    Lin SY; He L; Xie LP; Wang Y; Lin YX; Cao YY; Yan WL; Liu F; Huang GY
    Trials; 2021 Dec; 22(1):898. PubMed ID: 34895290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH
    PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.
    Lim YJ; Jung JW
    Yonsei Med J; 2014 Sep; 55(5):1260-6. PubMed ID: 25048483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM; Silverman ED; McCrindle BW; Yeung RS
    J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose versus low-dose intravenous immunoglobulin for treatment of children with Kawasaki disease weighing 25 kg or more.
    Suzuki T; Michihata N; Yoshikawa T; Hata T; Matsui H; Fushimi K; Yasunaga H
    Eur J Pediatr; 2020 Dec; 179(12):1901-1907. PubMed ID: 32862279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
    Qin LJ; Wang HW; Hu XF; Liu QJ; Shi H; Wei YX; Chen QJ; Cheng PX
    Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):891-5. PubMed ID: 17254453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reevaluation of the efficacy of intravenous gammaglobulin in the prevention and treatment of coronary artery lesion in Kawasaki disease.
    Qin L; Saumu MT; Wang H; Shi H; Hu X; Cheng P
    J Huazhong Univ Sci Technolog Med Sci; 2005; 25(3):348-50, 370. PubMed ID: 16201293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of intravenous immunoglobulin alone and intravenous immunoglobulin combined with high-dose aspirin in the acute stage of Kawasaki disease: study protocol for a randomized controlled trial.
    Kuo HC; Guo MM; Lo MH; Hsieh KS; Huang YH
    BMC Pediatr; 2018 Jun; 18(1):200. PubMed ID: 29933749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
    Roberts SC; Jain S; Tremoulet AH; Kim KK; Burns JC; ; Anand V; Anderson M; Ang J; Ansusinha E; Arditi M; Ashouri N; Bartlett A; Chatterjee A; DeBiasi R; Dekker C; DeZure C; Didion L; Dominguez S; El Feghaly R; Erdem G; Halasa N; Harahsheh A; Jackson MA; Jaggi P; Jain S; Jone PN; Kaushik N; Kurio G; Lillian A; Lloyd D; Manaloor J; McNelis A; Michalik DE; Newburger J; Newcomer C; Perkins T; Portman M; Romero J; Ronis T; Rowley A; Schneider K; Schuster J; Tejtel SKS; Sharma K; Simonsen K; Szmuszkovicz J; Truong D; Wood J; Yeh S
    Contemp Clin Trials; 2019 Apr; 79():98-103. PubMed ID: 30840903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin.
    Platt B; Belarski E; Manaloor J; Ofner S; Carroll AE; John CC; Wood JB
    JAMA Netw Open; 2020 Jan; 3(1):e1918565. PubMed ID: 31899532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
    Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.
    Nanishi E; Nishio H; Takada H; Yamamura K; Fukazawa M; Furuno K; Mizuno Y; Saigo K; Kadoya R; Ohbuchi N; Onoe Y; Yamashita H; Nakayama H; Hara T; Ohno T; Takahashi Y; Hatae K; Harada T; Shimose T; Kishimoto J; Ohga S; Hara T
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28684643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial.
    Fukui S; Seki M; Minami T; Kotani K; Oka K; Yokomizo A; Matsubara D; Sato T; Nozaki Y; Saito M; Kikuchi Y; Miyamoto K; Monden Y; Yamagata T
    Pediatr Rheumatol Online J; 2021 Jul; 19(1):107. PubMed ID: 34217297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of different doses of aspirin on the prognosis of Kawasaki disease.
    Wang J; Chen H; Shi H; Zhang X; Shao Y; Hang B; Xu Z; Rong X; Chu M; Qiu H
    Pediatr Rheumatol Online J; 2020 Jun; 18(1):48. PubMed ID: 32527316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
    J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.